Department of Immunology and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Nat Rev Cancer. 2010 Mar;10(3):213-21. doi: 10.1038/nrc2804. Epub 2010 Feb 19.
The year 2009 marked the fiftieth anniversary of the first successful allogeneic haematopoietic stem cell transplant (HSCT). The field of HSCT has pioneered some of the most exciting areas of research today. HSCT was the original stem cell therapy, the first cancer immune therapy and the earliest example of individualized cancer therapy. In this Timeline article we review the history of the development of HSCT and major advances made in the past 50 years. We highlight accomplishments made by researchers who continue to strive to improve outcomes for patients and increase the availability of this potentially life-saving therapy for patients with otherwise incurable malignancies.
2009 年标志着首例异基因造血干细胞移植（HSCT）成功的五十周年。HSCT 领域开创了当今一些最令人兴奋的研究领域。HSCT 是最初的干细胞疗法，是第一种癌症免疫疗法，也是最早的个体化癌症治疗范例。在这篇时间线文章中，我们回顾了 HSCT 的发展历史以及过去 50 年来取得的重大进展。我们重点介绍了那些不断努力改善患者治疗效果并增加这种对其他方法无法治愈的恶性肿瘤具有潜在救命作用的治疗方法可及性的研究人员的成就。
